Nanomedicine in cardiovascular therapy: recent advancements
- PMID: 22894635
- DOI: 10.1586/erc.12.41
Nanomedicine in cardiovascular therapy: recent advancements
Abstract
Cardiovascular disease (CVD) is comprised of a group of disorders affecting the heart and blood vessels of the human body and is one of the leading causes of death worldwide. Current therapy for CVD is limited to the treatment of already established disease, and it includes pharmacological and/or surgical procedures, such as percutaneous coronary intervention with stenting and coronary artery bypass grafting. However, lots of complications have been raised with these modalities of treatment, including systemic toxicity with medication, stent thrombosis with percutaneous coronary intervention and nonsurgical candidate patients for coronary artery bypass grafting. Nanomedicine has emerged as a potential strategy in dealing with these obstacles. Applications of nanotechnology in medicine are already underway and offer tremendous promise. This review explores the recent developments of nanotechnology in the field of CVD and gives an insight into its potential for diagnostics and therapeutics applications. The authors also explore the characteristics of the widely used biocompatible nanomaterials for this purpose and evaluate their opportunities and challenges for developing novel nanobiotechnological tools with high efficacy for biomedical applications, such as radiological imaging, vascular implants, gene therapy, myocardial infarction and targeted delivery systems.
Similar articles
-
Nanotechnology in cardiovascular medicine.Catheter Cardiovasc Interv. 2007 Apr 1;69(5):643-54. doi: 10.1002/ccd.21060. Catheter Cardiovasc Interv. 2007. PMID: 17390307 Review.
-
Novel applications of nanotechnology in medicine.Indian J Med Res. 2009 Dec;130(6):689-701. Indian J Med Res. 2009. PMID: 20090129 Review.
-
Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles.Nanomedicine (Lond). 2006 Oct;1(3):321-9. doi: 10.2217/17435889.1.3.321. Nanomedicine (Lond). 2006. PMID: 17716162 Review.
-
New technology and clinical applications of nanomedicine.Med Clin North Am. 2007 Sep;91(5):845-62. doi: 10.1016/j.mcna.2007.05.004. Med Clin North Am. 2007. PMID: 17826105 Review.
-
Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology.Curr Pharm Des. 2015;21(30):4479-97. doi: 10.2174/1381612821666150817104635. Curr Pharm Des. 2015. PMID: 26278923 Review.
Cited by
-
Therapeutic Efficacy of an ω-3-Fatty Acid-Containing 17-β Estradiol Nano-Delivery System against Experimental Atherosclerosis.PLoS One. 2016 Feb 3;11(2):e0147337. doi: 10.1371/journal.pone.0147337. eCollection 2016. PLoS One. 2016. PMID: 26840601 Free PMC article.
-
Bioabsorbable stent quo vadis: a case for nano-theranostics.Theranostics. 2014 Feb 22;4(5):514-33. doi: 10.7150/thno.8137. eCollection 2014. Theranostics. 2014. PMID: 24672583 Free PMC article. Review.
-
Study of charge-dependent transport and toxicity of peptide-functionalized silver nanoparticles using zebrafish embryos and single nanoparticle plasmonic spectroscopy.Chem Res Toxicol. 2013 Jun 17;26(6):904-17. doi: 10.1021/tx400087d. Epub 2013 May 17. Chem Res Toxicol. 2013. PMID: 23621491 Free PMC article.
-
Bioactive baculovirus nanohybrids for stent based rapid vascular re-endothelialization.Sci Rep. 2013;3:2366. doi: 10.1038/srep02366. Sci Rep. 2013. PMID: 23917680 Free PMC article.
-
Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities.Int J Mol Sci. 2023 Mar 8;24(6):5205. doi: 10.3390/ijms24065205. Int J Mol Sci. 2023. PMID: 36982284 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources